CRISM Therapeutics Corporation
02 October 2026
2 October 2026
CRISM Therapeutics Corporation
(‘CRISM’, ‘CRISM Therapeutics’ or the ‘Company’)
Notice of AGM
CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, confirms that the Annual General Meeting ("AGM") will take place at 11:00am on Tuesday 27 October 2026 at the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London EC4R 3TT. Further details are set out in the Notice of AGM which has been posted to shareholders today.
A copy Notice of AGM can be accessed from the Company´s website at:
https://www.crismtherapeutics.com/investors/documents-circulars/
-Ends-
Enquiries:
|
Company |
Nomad and Broker |
Financial PR |
|
CRISM Therapeutics Corporation |
S.P. Angel Corporate Finance LLP |
Burson Buchanan |
|
Andrew Webb, CEO Chris McConville, CSO |
David Hignell Vadim Alexandre Adam Cowl |
Henry Harrison Topham Jamie Hooper CRISM@buchanancomms.co.uk |
|
via Burson Buchanan |
+44 (0) 20 3470 0470 |
+44 (0) 20 7466 5000 |
About CRISM Therapeutics Corporation
CRISM Therapeutics Corporationhas developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.
ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.
CRISM has commenced recruitment at the Company’s first clinical site for its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma.
For more information please visit:https://www.crismtherapeutics.com/
The Company's LEI is 213800XFW6MKVCHHPW88.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.